BioPharma Resources

Drug Trial Radar · NCT02396459

Triac Trial II in MCT8 Deficiency Patients

Tiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial II

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

22

Actual

Start

Dec 7, 2020

Primary completion

Jul 18, 2027

Study completion Aug 18, 2027

Sponsor

Sponsor type
Industry
Collaborators
Erasmus Medical Center
First posted
Mar 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, up to 30 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the effect of treatment with tiratricol (also called Triac) in young boys (≤30 months) with MCT8 deficiency (also called the Allan-Herndon-Dudley syndrome (AHDS)). The hypothesis tested is that treatment with tiratricol will have a beneficial effect on the hypothyroid state in the brain as well as the hyperthyroid state in peripheral organs and tissues in these patients. Patients will initially be treated for 96 weeks with tiratricol, treatment effect on neurodevelopment impairment caused by hypothyroidism and peripheral thyrotoxicosis will be evaluated after 96 weeks treatment. Patients will be offered to continue on treatment for an additional 3 years.

Conditions

  • Allan-Herndon-Dudley Syndrome

Interventions

  • TiratricolDrug

    Tiratricol, individually titrated dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gross Motor Function Measure 88 (GMFM 88) total scoreTime frame: 96 weeks, Year 3, Year 4 and Year 5
  2. Bayley Scales of Infant Development III Gross Motor Skill Domain scoreTime frame: 96 weeks, Year 3, Year 4 and Year 5

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Oregon Health & Science University (OHSU) Doernbecher Childrens Hospital

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Charles University and Motol University Hospital; The department of peadiatrics of the 2nd faculty of medicine

    Prague, Czechia

  • Charité - Universitätsmedizin Berlin Institut fur experimental paediatrische endokrinologie

    Berlin, Germany

  • Erasmus MC

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.